1 October 2025
Roche Launches Tender Offer for 89bio at $14.50 Per Share Plus CVR
Tender offer expires Oct 29, 2025. Includes CVR up to $6.00. Requires majority share tender, no financing condition. Second-step merger follows at same terms. Completion expected Q4 2025.
